Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income: 2020-2024

Historic Net Income for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to -$72.7 million.

  • Monte Rosa Therapeutics' Net Income fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.52%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.27% up from last year.
  • As of FY2024, Monte Rosa Therapeutics' Net Income stood at -$72.7 million, which was up 46.27% from -$135.4 million recorded in FY2023.
  • Monte Rosa Therapeutics' Net Income's 5-year high stood at -$25.8 million during FY2020, with a 5-year trough of -$135.4 million in FY2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Net Income value was -$108.5 million (recorded in 2022), while the average stood at -$105.5 million.
  • In the last 5 years, Monte Rosa Therapeutics' Net Income crashed by 148.62% in 2021 and then soared by 46.27% in 2024.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Net Income stood at -$25.8 million in 2020, then plummeted by 148.62% to -$64.1 million in 2021, then plummeted by 69.34% to -$108.5 million in 2022, then decreased by 24.75% to -$135.4 million in 2023, then surged by 46.27% to -$72.7 million in 2024.